Radha Patel
Family · Tifton, GANPI 1285190918
Payments from drug & device makers
Across 185 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Johnson & Johnson$712
- E.r. Squibb & Sons, L.L.C.$516
- Novartis$290
- AstraZeneca$277
- Amgen$225
- plus $1K from 11 others
What the payments were for
- Travel & lodging$67116%
- Food & beverage$3,33080%
- Education$1604%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,100 |
| Johnson & Johnson | 55 | $712 |
| E.r. Squibb & Sons, L.L.C. | 29 | $516 |
| Novartis | 16 | $290 |
| AstraZeneca(2 entities) | 9 | $277 |
| Amgen | 13 | $225 |
| Pfizer | 11 | $192 |
| Daiichi Sankyo Inc. | 8 | $185 |
| Bayer | 9 | $165 |
| Merck | 8 | $149 |
| Boehringer Ingelheim | 6 | $143 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $70 |
| Medtronic | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Nobel Biocare USA | 1 | $26 |
| Novo Nordisk | 1 | $26 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$970
How this compares
$4,160 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 121 | $179,719 |
| EliquisApixaban | 75 | $98,889 |
| XareltoRivaroxaban | 73 | $82,957 |
| FarxigaDapagliflozin Propanediol | 71 | $81,858 |
| Repatha SyringeEvolocumab | 23 | $26,807 |
| JardianceEmpagliflozin | 24 | $25,768 |
| Ranolazine ErRanolazine | 149 | $14,052 |
| Repatha SureclickEvolocumab | 15 | $9,316 |
| Hydralazine Hcl | 194 | $2,268 |
| Amlodipine Besylate | 317 | $2,256 |
| Losartan Potassium | 202 | $2,043 |
| Flecainide Acetate | 34 | $1,862 |
| Metoprolol Succinate | 117 | $1,708 |
| Atorvastatin Calcium | 141 | $1,700 |
| SotalolSotalol Hcl | 85 | $1,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $290 | $179,719121 claims |
| PfizerEliquis | $192 | $98,88975 claims |
| Johnson & JohnsonXarelto | $712 | $82,95773 claims |
| AstraZenecaFarxiga | $277 | $81,85871 claims |
| Boehringer IngelheimJardiance | $143 | $25,76824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Tifton
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.